Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Press office

refresh
Insert captcha code.

References

 
ingresso fisheye

For any questions please contact us at the following numbers:

Communication & Public Affairs
 Tel:
 
+39.0331.581.380
+39.333.84.25.690
 

Press Release

 
Al prossimo AACR Nerviano Medical Sciences presenterà le novità su due efficaci nuovi inibitori oncologici, selettivi e tollerati Nerviano, 31 marzo 2017 – Con un track record di 8 molecole licenziate in sei anni ed una robusta pipeline con diversi esempi dell’oncologia di precisione, il Campus di Nerviano Medical Sciences può vantare anche progetti in ricerca preclinica che stanno avanzando con successo e che rappresentano le prospettive future. Le nuove evidenze al prossimo Meeting dell’American Association for Cancer... Read more
Trovagene and Nerviano Announce License Agreement for therapeutic candidate PCM-075 Nerviano, Italy (March 15, San Diego, CA Trovagene, Inc. NASDAQ: TROV) - Trovagene, a precision medicine biotechnology company and Nerviano Medical Sciences, S.r.l., a leading oncology discovery organization, today announced that they have signed a license agreement that grants Trovagene exclusive global development and commercialization rights to NMS-1286937, which Trovagene refers to as... Read more
Ignyta's Updated Phase 1 Data on Safety, Anti-Tumor Activity and CNS Activity of Entrectinib in Cancers with TRK, ROS1 or ALK Fusions Published in Cancer Discovery Milan, Italy 9th February 2017 SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that updated results from two Phase 1 trials of entrectinib—the company's investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions—were published in the... Read more
NMS Group partecipa al programma PhD ITalents e offre 6 posizioni altamente qualificate a giovani ricercatori Nerviano, Italia 2 Febbraio 2017 – Saranno sei i giovani Dottori in Ricerca che entreranno a far parte del Gruppo di Nerviano. La selezione è avvenuta nell’ambito di PhD ITalents, il progetto pilota gestito dalla Fondazione CRUI su incarico del MIUR ed in partenariato con Confindustria, nato con l’obiettivo di avvicinare il mondo accademico ed il mondo del lavoro, favorendo l’inserimento... Read more
Late-Breaking Oral Plenary Presentation of a Novel Entrectinib Combination Regimen at the 2016 EORTC-NCI-AACR Annual Meeting Nerviano, Italy 2nd December 2016SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced data examining the combination of entrectinib and trametinib in overcoming resistance to TRK inhibition during a late-breaking oral plenary presentation (during the Exceptional Response and Expected Resistance Session) at... Read more
Nerviano Medical Sciences presents data regarding a potent new cytotoxic molecule for ADC generation Nerviano, Italy 13th October 2016 – At the 7th World Summit focused on ADCs (San Diego, CA), Nerviano Medical Sciences presented new data regarding the immunoconjugate drugs field, an area of intense interest in the Oncology R&D sector. During the event NMS researchers described the targeted anticancer effects obtained in preclinical models with an ADC obtained by combining the thienoindole... Read more
MediaPharma Licenses Nerviano Medical Sciences’ Drug-Linker Technology to Develop Novel Antibody Drug Conjugate Reiden (Switzerland), Chieti (Italy) and Nerviano (Italy) – 07 September 2016 – MediaPharma (MP), a biotech company focusing on the discovery and development of monoclonal antibodies, bispecifics and antibody drug conjugates (ADCs) against new targets in oncology and Nerviano Medical Sciences (Nerviano), a company of the NMS Group dedicated to the discovery and development of breakthrough... Read more
La nostra Notte della Ricerca Nerviano, Italy 4th September 2016  Il lungo percorso di ricerca e sviluppo di un nuovo farmaco oncologico è il risultato di un affascinante lavoro di squadra, al quale contribuiscono diverse conoscenze, tecnologie e tanta passione. Per la Seconda Edizione della notte nervianese sarà possibile visitare i laboratori di Ricerca e assistere alle dimostrazioni pratiche in 3 diversi percorsi... Read more

MediaPharma Licenses Nerviano Medical Sciences’ Drug-Linker Technology to Develop Novel Antibody Drug Conjugate

Reiden (Switzerland), Chieti (Italy) and Nerviano (Italy) – 07 September 2016 – MediaPharma (MP), a biotech company focusing on the discovery and development of monoclonal antibodies, bispecifics and antibody drug conjugates (ADCs) against new targets in oncology and Nerviano Medical Sciences (Nerviano), a company of the NMS Group dedicated to the discovery and development of breakthrough treatments for cancer, today announce that they have signed a license and a supply agreement that will allow MP to develop Nerviano’s ‘payload’ (drug-linker) technology on a MP-exclusive target for an ADC designed to meet unmet needs in the field of cancer.

As a result of this agreement, Nerviano will receive undisclosed fees, development linked milestones and royalties for granting MP access to its technology. Nerviano will lead the effort in the manufacture and supply of its payload technology.

Nerviano’s payload technology of new DNA intercalating agents is based on a proprietary thienoindole scaffold, characterized both by potent antitumor activity and by physicochemical properties that are highly compatible with deployment as antibody payloads. Nerviano’s core technologies in the field further include: medicinal chemistry expertise, know-how for establishing proof of concept, GMP manufacturing of payloads as well as efficacy and safety profiling of ADC’s.

Jean-Frédéric Sauniere, M.D., Ph.D., Chief Executive Officer at MediaPharma, commented: “This collaboration with NMS brings to Mediapharma great assets to complement our expertise in immuno-oncology, in particular for the creation of new ADCs against key targets and therefore offering hope for our patients ”

Stefano Iacobelli, M,D. Co-founder and Chief Scientific Officer at MediaPharma, commented: “Antibody-Drug Conjugates (ADCs) are a developing area of cancer drug technology that offers selective targeting of cancer cells. This targeted ADC approach has the potential to optimize the delivery of the cancer drug to the tumor. This means that, in contrast to traditional chemotherapy these novel agents target and attack the cancer cell so that healthy cells are less severely affected. So far, three ADCs have been approved for cancer treatment, but all leading Pharmas are in the process of developing and launching ADCs therapeutics."

Barbara Marenco, President of Nerviano Medical Sciences, commented: “We are very pleased to have signed this licensing deal with MediaPharma. This new agreement marks an additional achievement in our strategic alliances objectives and we are excited about the prospect of expanding the potential of our payload technology platform through new valuable collaborations.”

 

 

 
To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.